Myfortic (Mycophenolic Acid)

Mycophenolic acid blocks the enzyme inosine monophosphate dehydrogenase, which is needed for the synthesis of guanosine nucleotides. This inhibition limits the proliferation of T‑ and B‑lymphocytes, the immune cells responsible for attacking a transplanted organ, thereby reducing the likelihood of rejection.

The exact dose of Myfortic is individualized by the prescribing physician based on the type of transplant, patient weight, kidney function and other medications. Dosage adjustments are made according to therapeutic response and laboratory monitoring.

Myfortic is classified as pregnancy category D, indicating evidence of risk to the fetus. It should not be used during pregnancy unless the potential benefit justifies the risk. Limited data are available for breastfeeding; therefore, caution is advised and alternative therapy may be considered.

To request Myfortic, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolic acid) is an antimetabolite that specifically inhibits lymphocyte proliferation, whereas calcineurin inhibitors such as cyclosporine or tacrolimus act on T‑cell activation pathways. Myfortic is often used in combination with these agents to achieve synergistic immunosuppression while offering a different side‑effect profile.

Myfortic tablets should be stored at temperatures below 25 °C, in the original container to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Myfortic is taken orally as a delayed‑release tablet, usually twice daily, with food to improve tolerability. The tablet should be swallowed whole; it must not be crushed, chewed, or split, as this can alter the release characteristics and affect drug absorption.

Serious risks include severe infections due to immune suppression, leukopenia or anemia that can lead to bleeding or fatigue, liver toxicity, and rare cases of malignancy such as post‑transplant lymphoproliferative disorder. Patients should be monitored regularly for these complications.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any tablet excipients. It should also be avoided in individuals with severe, uncontrolled infections, active malignancy, or those who are pregnant without a clear benefit outweighing fetal risk.